These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Castell D Expert Opin Pharmacother; 2005 Nov; 6(14):2501-10. PubMed ID: 16259581 [TBL] [Abstract][Full Text] [Related]
9. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension. Johnson CE; Cober MP; Ludwig JL Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960 [TBL] [Abstract][Full Text] [Related]
10. In vitro study on capsule formulations of omeprazole containing enteric coated granules. Pandey VP; Phanindrudu A; Manavalan R; Livingston J Boll Chim Farm; 2002; 141(6):419-22. PubMed ID: 12577509 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. Tsoi KK; Lau JY; Sung JJ Gastrointest Endosc; 2008 Jun; 67(7):1056-63. PubMed ID: 18407271 [TBL] [Abstract][Full Text] [Related]
12. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537 [TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. Devlin JW; Welage LS; Olsen KM Ann Pharmacother; 2005 Nov; 39(11):1844-51. PubMed ID: 16204393 [TBL] [Abstract][Full Text] [Related]
14. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408 [TBL] [Abstract][Full Text] [Related]
15. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Metz DC; Vakily M; Dixit T; Mulford D Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580 [TBL] [Abstract][Full Text] [Related]
16. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Miner PB; Allgood LD; Grender JM Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225 [TBL] [Abstract][Full Text] [Related]
17. Stress-induced ulcer bleeding in critically ill patients. Ali T; Harty RF Gastroenterol Clin North Am; 2009 Jun; 38(2):245-65. PubMed ID: 19446257 [TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Devlin JW; Welage LS; Olsen KM Ann Pharmacother; 2005 Oct; 39(10):1667-77. PubMed ID: 16118266 [TBL] [Abstract][Full Text] [Related]
19. Effects of preoperative administration of omeprazole on bleeding after endoscopic submucosal dissection: a prospective randomized controlled trial. Ono S; Kato M; Ono Y; Nakagawa M; Nakagawa S; Shimizu Y; Asaka M Endoscopy; 2009 Apr; 41(4):299-303. PubMed ID: 19340731 [TBL] [Abstract][Full Text] [Related]
20. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]